FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is a group of inventions, related to medicine, namely to neurology. A method of avoiding inhibition of myelination with Schwann cells and a method of stimulating myelination in a patient with a disease or disorder, associated with lower levels of myelination, which includes selection of the patient with a disease or disorder, associated with the lower levels of myelination, and introduction of glial growth factor 2 (GGF2) to the patient, including introduction of 500 ng+/-15% GGF2 per a kg of the patient's body weight. Also claimed is a pharmaceutical composition for application for treatment of the patient with a disease or disorder, associated with the lower levels of myelination, which contains GGF2 or a domain EGFL and an inhibitor of the pathway with participation of Mekl/Erk. The inhibitor of the pathway with participation of Mekl/Erk is selected from the group, consisting of Arctigenin, PD98059, SB202190, SB203580, SP600125, U0126, tipifarnib (Zarnesta), sorafenib, ISIS 5132, CI-1040 and PD 0325901.
EFFECT: group of inventions provides stimulation of myelination.
29 cl, 12 dwg
